 |
인쇄하기
취소
|
Additional indication for Revanex granted
The Korean Food and Drug Administration (KFDA) said on June 26 it has granted Yuhan Corp. an additional indication for their novel proton pump inhibitor Revanex (revaprazan).
Revanex is now indicated for the prevention of gastritis and its prior indication included its use for the prevention of duodenal ulcers.
It took 12 years for the company to develop the drug with an investment of 40 ...
Revanex is now indicated for the prevention of gastritis and its prior indication included its use for the prevention of duodenal ulcers.
It took 12 years for the company to develop the drug with an investment of 40 ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.